Natco Pharma Ltd (NATCOPHARM):企業の財務・戦略的SWOT分析

◆英語タイトル:Natco Pharma Ltd (NATCOPHARM) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C9033
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Natco Pharma Ltd (NATCOPHARM) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Natco Pharma Ltd (Natco Pharma) focuses on the research, development, manufacture and commercialization of pharmaceutical substances and finished dosage forms. The company offers finished dosage forms in capsule, injection and tablet. Its products are indicated to treat multiple sclerosis, influenza infection, multiple myeloma, leukemia, Crohn’s disease, hypertension, Myelodysplastic syndrome and prostate cancer and others. Natco Pharma offers active pharmaceutical ingredients (APIs) for the domestic and international markets. It operates API and finished dosage facilities and a research center in India. The company operates in India, the US, Canada, and Europe. Natco Pharma is headquartered in Hyderabad, Telangana, India.

Natco Pharma Ltd Key Recent Developments

Aug 08,2018: NATCO records INR 574.5 Crores consolidated revenue and INR 181.1 Crore of profit, after tax, for the First Quarter, FY2018-19
May 23,2018: NATCO records INR 2,242 Crore consolidated revenue and INR 695 Crore of profit, after tax, for the full year ended March 2018
Feb 17,2018: USFDA completes inspection of Natco’s Mekaguda API facility with zero observations
Feb 06,2018: NATCO records INR 573.6 Crore revenue and INR 217.4 Crore of Profit, after tax, for the Third Quarter, FY 2017-18
Aug 07,2017: NATCO Pharma Reports Financial Results For The Quarter Ended 30 June 2017

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Natco Pharma Ltd – Key Facts 6
Natco Pharma Ltd – Key Employees 7
Natco Pharma Ltd – Key Employee Biographies 9
Natco Pharma Ltd – Major Products and Services 10
Natco Pharma Ltd – History 11
Natco Pharma Ltd – Company Statement 14
Natco Pharma Ltd – Locations And Subsidiaries 16
Head Office 16
Other Locations & Subsidiaries 16
Joint Venture 17
Section 2 – Company Analysis 18
Company Overview 18
Natco Pharma Ltd – Business Description 19
Business Segment: Active Pharmaceutical Ingredients 19
Overview 19
Performance 19
Business Segment: Domestic Formulations 19
Overview 19
Performance 19
Business Segment: International Formulations 20
Overview 20
Performance 20
Business Segment: Others 20
Overview 20
Performance 20
Business Segment: Outside India 20
Capital Expenditure 20
Geographical Segment: India 20
Performance 20
R&D Overview 20
Natco Pharma Ltd – Corporate Strategy 21
Natco Pharma Ltd – SWOT Analysis 22
SWOT Analysis – Overview 22
Natco Pharma Ltd – Strengths 22
Natco Pharma Ltd – Weaknesses 24
Natco Pharma Ltd – Opportunities 25
Natco Pharma Ltd – Threats 26
Natco Pharma Ltd – Key Competitors 27
Section 3 – Company Financial Ratios 28
Financial Ratios – Capital Market Ratios 28
Financial Ratios – Annual Ratios 29
Performance Chart 32
Financial Performance 32
Financial Ratios – Interim Ratios 33
Financial Ratios – Ratio Charts 34
Section 4 – Company’s Lifesciences Financial Deals and Alliances 35
Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 35
Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 36
Natco Pharma Ltd, Recent Deals Summary 37
Section 5 – Company’s Recent Developments 38
Aug 08, 2018: NATCO records INR 574.5 Crores consolidated revenue and INR 181.1 Crore of profit, after tax, for the First Quarter, FY2018-19 38
May 23, 2018: NATCO records INR 2,242 Crore consolidated revenue and INR 695 Crore of profit, after tax, for the full year ended March 2018 39
Feb 17, 2018: USFDA completes inspection of Natco’s Mekaguda API facility with zero observations 40
Feb 06, 2018: NATCO records INR 573.6 Crore revenue and INR 217.4 Crore of Profit, after tax, for the Third Quarter, FY 2017-18 41
Aug 07, 2017: NATCO Pharma Reports Financial Results For The Quarter Ended 30 June 2017 42
Aug 07, 2017: Natco Pharma Announces Resignation of Directors 43
Jul 20, 2017: NATCO receives establishment inspection report (EIR) from U.S. food and drug administration (FDA) 44
May 30, 2017: NATCO records INR 2078.9 Crore total consolidated revenue and INR 486.0 Crore of profit, after tax, for the full year ended March 2017 45
Feb 14, 2017: NATCO records INR 685.13 Crore total consolidated revenue and INR 194.76 Crore of profit, after tax, for the Third Quarter, FY 2017 14 February 2017 46
Jan 25, 2017: NATCO updates on USFDA inspection at its Kothur Formulation Facility 47
Section 6 – Appendix 48
Methodology 48
Ratio Definitions 48
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Natco Pharma Ltd, Key Facts 6
Natco Pharma Ltd, Key Employees 7
Natco Pharma Ltd, Key Employee Biographies 9
Natco Pharma Ltd, Major Products and Services 10
Natco Pharma Ltd, History 11
Natco Pharma Ltd, Other Locations 16
Natco Pharma Ltd, Subsidiaries 16
Natco Pharma Ltd, Joint Venture 17
Natco Pharma Ltd, Key Competitors 27
Natco Pharma Ltd, Ratios based on current share price 28
Natco Pharma Ltd, Annual Ratios 29
Natco Pharma Ltd, Annual Ratios (Cont...1) 30
Natco Pharma Ltd, Annual Ratios (Cont...2) 31
Natco Pharma Ltd, Interim Ratios 33
Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 35
Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 36
Natco Pharma Ltd, Recent Deals Summary 37
Currency Codes 48
Capital Market Ratios 48
Equity Ratios 49
Profitability Ratios 49
Cost Ratios 50
Liquidity Ratios 50
Leverage Ratios 51
Efficiency Ratios 51

List of Figures
Natco Pharma Ltd, Performance Chart (2014 - 2018) 32
Natco Pharma Ltd, Ratio Charts 34
Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 35
Natco Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 36

★海外企業調査レポート[Natco Pharma Ltd (NATCOPHARM):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Pioneer Distilleries Limited:企業の戦略・SWOT・財務情報
    Pioneer Distilleries Limited - Strategy, SWOT and Corporate Finance Report Summary Pioneer Distilleries Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Cathay Pacific Airways Limited
    Cathay Pacific Airways Limited - Strategy, SWOT and Corporate Finance Report Summary Cathay Pacific Airways Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Oriental Cuisines Private Limited:企業の戦略・SWOT・財務分析
    Oriental Cuisines Private Limited - Strategy, SWOT and Corporate Finance Report Summary Oriental Cuisines Private Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • MannKind Corp (MNKD)-医療機器分野:企業M&A・提携分析
    Summary MannKind Corp (MannKind) is a biopharmaceutical company that discovers, develops and commercializes therapeutic products to treat diseases such as diabetes. The company’s lead product, Afrezza is a rapid-acting, inhaled insulin used to control high blood sugar in adults with type 1 and type …
  • Tessi S.A. (TES):企業の財務・戦略的SWOT分析
    Tessi S.A. (TES) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Attica Bank S.A.
    Attica Bank S.A. - Strategy, SWOT and Corporate Finance Report Summary Attica Bank S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Capcom Co Ltd (9697):企業の財務・戦略的SWOT分析
    Capcom Co Ltd (9697) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Syros Pharmaceuticals Inc (SYRS):企業の財務・戦略的SWOT分析
    Summary Syros Pharmaceuticals Inc (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company offers its pipeline products under clinical trials include SY-1425, an oral, potent and selective RARa agonist that …
  • Corpak MedSystems Inc:医療機器:M&Aディール及び事業提携情報
    Summary Corpak MedSystems Inc (Corpak), a subsidiary of Halyard Health Inc is a medical device company that manufactures and markets enteral feeding safety devices. The company offers products such as cortrak systems, gastrostomy, nasoenteric systems, gastric decompression, NICU products and accesso …
  • Aptose Biosciences Inc (APTO):製薬・医療:M&Aディール及び事業提携情報
    Summary Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company which focuses on diagnostics, therapies and treatment for patients with life-threatening cancers. The company advances in new therapeutics which focuses on cellular targets of cancer research coupled with companion dia …
  • Global Ports Holding PLC (GPH):企業の財務・戦略的SWOT分析
    Global Ports Holding PLC (GPH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Daily Mail & General Trust plc (DMGT):企業の財務・戦略的SWOT分析
    Daily Mail & General Trust plc (DMGT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Akebia Therapeutics Inc (AKBA):製薬・医療:M&Aディール及び事業提携情報
    Summary Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia inducible factor for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF …
  • Hammerson plc:企業のM&A・事業提携・投資動向
    Hammerson plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Hammerson plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Intrexon Corp (XON):企業の財務・戦略的SWOT分析
    Summary Intrexon Corp (Intrexon), formerly Genomatix Corp is a synthetic biology service provider. The company operates through its divisions and units such as cell engineering, data sciences and computational biology, information technology (IT), actobiotics, molecular engineering, agricultural bio …
  • Wien Energie GmbH:企業の戦略的SWOT分析
    Wien Energie GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • CME Group Inc:企業の戦略・SWOT・財務情報
    CME Group Inc - Strategy, SWOT and Corporate Finance Report Summary CME Group Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Taconic Biosciences Inc:医療機器:M&Aディール及び事業提携情報
    Summary Taconic Biosciences Inc (Taconic), formerly Taconic Farms Inc is a research model provider that offers animal health models and laboratory services. The company’s products include taconic transgenic mouse models, emerging models, cryopreserved models, traditional models, diet induced obese, …
  • Postal Savings Bank of China Co., Ltd. (1658):企業の財務・戦略的SWOT分析
    Postal Savings Bank of China Co., Ltd. (1658) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Royal College of Surgeons Ireland:製薬・医療:M&Aディール及び事業提携情報
    Summary Royal College of Surgeons Ireland (RCSI) is an educational institution that offers medical education and training in healthcare professions at undergraduate and postgraduate levels. The institute provides undergraduate courses in nursing, postgraduate research, leadership courses, and surgic …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆